Oncology Medications

EXKIVITY™
(mobocertinib)

EXKIVITY now available from Onco360!

EXKIVITY(mobocertinib) is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Dosage Form and Strength1

EXKIVITY is available as 40 mg capsules in 120-count pill bottles (NDC 63020-040-12). 

Dosage and Administration

The recommended dose of EXKIVITY is 160 mg (4 capsules) orally once daily with or without food.

For complete details, visit Exkivity

How to Order

Call

Call 877-662-6633.

Fax

Download the Oral Rx
Oncology Order Form and
fax it to 877-662-6355.
Oral Order Form

e-Prescribe

e-Prescribe to Onco360 in Louisville, KY 40223, or NPI# 1437577988 under the retail tab in your EMR/EHR or standalone e-prescribing application.

1EXKIVITYPrescribing Information: Takeda Pharmaceuticals America, Inc. EXKIVITY.com accessed 9/21. EXKIVITYis a trademark of Takeda Pharmaceuticals International AG.